AIMS: Chronic Chagas disease (ChD) has high morbimortality and loss in quality of life due to heart failure (HF). Pharmaceutical care (PC) optimizes clinical treatment and can improve quality of life in HF. We evaluated if PC improves quality of life of patients with ChD and HF. METHODS: Single-blinded, randomized, controlled trial that assigned adult patients with ChD and HF (81 patients; 61 ± 11 years; 48% male) to PC (n = 40) or standard care (n = 41). Quality of life according to SF-36 and Minnesota living with HF questionnaires, incidence of drug-related problems (DRPs), and adherence to medical treatment were determined at baseline and at every 3 months for 1 year. Intention-to-treat analyses were performed by mixed linear model to verify the treatment effect on the changes of these variables throughout the intervention period. RESULTS: Relative changes from baseline to 1 year of follow-up of the domains physical functioning (+16.6 vs -8.5; P < .001), role-physical (+34.0 vs +5.2; P = .01), general health (+19.4 vs -6.1; P < .001), vitality (+11.5 vs. -5.8; P = .003), social functioning (+7.5 vs -13.3; P = .002), and mental health (+9.0 vs -3.7; P = .006) of the SF-36 questionnaire and the Minnesota living with HF questionnaire score (-12.7 vs +4.8; P < .001) were superior in the PC group than in the standard care group. Adherence to medical treatment increased as early as after 3 months of follow-up and DRPs incidence decreased after 6 months of follow-up only in the PC group. CONCLUSIONS:Patients with ChD and HF who received PC presented improved quality of life, decrease in DRP frequency, and increase in medication adherence.
RCT Entities:
AIMS: Chronic Chagas disease (ChD) has high morbimortality and loss in quality of life due to heart failure (HF). Pharmaceutical care (PC) optimizes clinical treatment and can improve quality of life in HF. We evaluated if PC improves quality of life of patients with ChD and HF. METHODS: Single-blinded, randomized, controlled trial that assigned adult patients with ChD and HF (81 patients; 61 ± 11 years; 48% male) to PC (n = 40) or standard care (n = 41). Quality of life according to SF-36 and Minnesota living with HF questionnaires, incidence of drug-related problems (DRPs), and adherence to medical treatment were determined at baseline and at every 3 months for 1 year. Intention-to-treat analyses were performed by mixed linear model to verify the treatment effect on the changes of these variables throughout the intervention period. RESULTS: Relative changes from baseline to 1 year of follow-up of the domains physical functioning (+16.6 vs -8.5; P < .001), role-physical (+34.0 vs +5.2; P = .01), general health (+19.4 vs -6.1; P < .001), vitality (+11.5 vs. -5.8; P = .003), social functioning (+7.5 vs -13.3; P = .002), and mental health (+9.0 vs -3.7; P = .006) of the SF-36 questionnaire and the Minnesota living with HF questionnaire score (-12.7 vs +4.8; P < .001) were superior in the PC group than in the standard care group. Adherence to medical treatment increased as early as after 3 months of follow-up and DRPs incidence decreased after 6 months of follow-up only in the PC group. CONCLUSIONS:Patients with ChD and HF who received PC presented improved quality of life, decrease in DRP frequency, and increase in medication adherence.
Authors: Mariell Jessup; William T Abraham; Donald E Casey; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Marvin A Konstam; Donna M Mancini; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy Journal: Circulation Date: 2009-03-26 Impact factor: 29.690
Authors: João Carlos Pinto Dias; Alberto Novaes Ramos; Eliane Dias Gontijo; Alejandro Luquetti; Maria Aparecida Shikanai-Yasuda; José Rodrigues Coura; Rosália Morais Torres; José Renan da Cunha Melo; Eros Antonio de Almeida; Wilson de Oliveira; Antônio Carlos Silveira; Joffre Marcondes de Rezende; Fabiane Scalabrini Pinto; Antonio Walter Ferreira; Anis Rassi; Abílio Augusto Fragata; Andréa Silvestre de Sousa; Dalmo Correia; Ana Maria Jansen; Glaucia Manzan Queiroz Andrade; Constança Felícia De Paoli de Carvalho Britto; Ana Yecê das Neves Pinto; Anis Rassi; Dayse Elisabeth Campos; Fernando Abad-Franch; Silvana Eloi Santos; Egler Chiari; Alejandro Marcel Hasslocher-Moreno; Eliane Furtado Moreira; Divina Seila de Oliveira Marques; Eliane Lages Silva; José Antonio Marin-Neto; Lúcia Maria da Cunha Galvão; Sergio Salles Xavier; Sebastião Aldo da Silva Valente; Noêmia Barbosa Carvalho; Alessandra Viana Cardoso; Rafaella Albuquerque E Silva; Veruska Maia da Costa; Simone Monzani Vivaldini; Suelene Mamede Oliveira; Vera da Costa Valente; Mayara Maia Lima; Renato Vieira Alves Journal: Rev Soc Bras Med Trop Date: 2016-12 Impact factor: 1.581
Authors: Li Shen; Felix Ramires; Felipe Martinez; Luiz Carlos Bodanese; Luis Eduardo Echeverría; Efraín A Gómez; William T Abraham; Kenneth Dickstein; Lars Køber; Milton Packer; Jean L Rouleau; Scott D Solomon; Karl Swedberg; Michael R Zile; Pardeep S Jhund; Claudio R Gimpelewicz; John J V McMurray Journal: Circ Heart Fail Date: 2017-11 Impact factor: 8.790
Authors: J S Lapa; R M Saraiva; A M Hasslocher-Moreno; I Georg; A S Souza; S S Xavier; P E A A do Brasil Journal: Eur J Clin Microbiol Infect Dis Date: 2011-09-08 Impact factor: 3.267
Authors: Ataur R Khan; Zaki N Al-Abdul Lateef; Mohammad A Al Aithan; Montaser A Bu-Khamseen; Ibrahim Al Ibrahim; Shabbir A Khan Journal: J Family Community Med Date: 2012-01
Authors: Ana Requena-Méndez; Edelweiss Aldasoro; Elisa de Lazzari; Elisa Sicuri; Michael Brown; David A J Moore; Joaquim Gascon; Jose Muñoz Journal: PLoS Negl Trop Dis Date: 2015-02-13
Authors: Martin Schulz; Nina Griese-Mammen; Pia M Schumacher; Stefan D Anker; Friedrich Koehler; Christian Ruckes; Volker Rettig-Ewen; Rolf Wachter; Dietmar Trenk; Michael Böhm; Ulrich Laufs Journal: ESC Heart Fail Date: 2020-07-23
Authors: Roberto M Saraiva; Mauro Felippe F Mediano; Fernanda Sns Mendes; Gilberto Marcelo Sperandio da Silva; Henrique H Veloso; Luiz Henrique C Sangenis; Paula Simplício da Silva; Flavia Mazzoli-Rocha; Andréa S Sousa; Marcelo T Holanda; Alejandro M Hasslocher-Moreno Journal: World J Cardiol Date: 2021-12-26
Authors: Igor Lucas Geraldo Izalino de Almeida; Luciano Fonseca Lemos de Oliveira; Pedro Henrique Scheidt Figueiredo; Rafael Dias de Brito Oliveira; Thayrine Rosa Damasceno; Whesley Tanor Silva; Lucas Frois Fernandes de Oliveira; Matheus Ribeiro Ávila; Vanessa Pereira Lima; Ana Thereza Chaves Lages; Mauro Felippe Felix Mediano; Manoel Otávio Costa Rocha; Henrique Silveira Costa Journal: Rev Soc Bras Med Trop Date: 2022-03-14 Impact factor: 1.581
Authors: Guilherme Wesley Peixoto da Fonseca; Tania Garfias Macedo; Nicole Ebner; Marcelo Rodrigues Dos Santos; Francis Ribeiro de Souza; Charles Mady; Liliam Takayama; Rosa Maria Rodrigues Pereira; Wolfram Doehner; Stefan D Anker; Carlos Eduardo Negrão; Maria Janieire de Nazaré Nunes Alves; Stephan von Haehling Journal: ESC Heart Fail Date: 2020-08-28